Skip to main content

Alzheimers/Cognitive Impairment CELIA

Status: Closed to Enrollment

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia.

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA).

Shawn Kile
Shawn Kile
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?